Cargando…
Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation
BACKGROUND: Recent studies have proved that tenofovir disoproxil fumarate (TDF) is associated with a lower risk of hepatocellular carcinoma (HCC) occurrence in chronic hepatitis B (CHB) patients and HCC recurrence in patients who underwent hepatectomy when compared to ETV. However, it is unclear whe...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847063/ https://www.ncbi.nlm.nih.gov/pubmed/36650583 http://dx.doi.org/10.1186/s13027-022-00478-4 |
_version_ | 1784871352091541504 |
---|---|
author | Yang, Jianming Chen, Yewu Sun, Haobin Zhang, Xijian Wang, Jianfeng Liang, Zhixing Fu, Binsheng Zhang, Tong Yi, Shuhong Deng, Yinan Yang, Yang |
author_facet | Yang, Jianming Chen, Yewu Sun, Haobin Zhang, Xijian Wang, Jianfeng Liang, Zhixing Fu, Binsheng Zhang, Tong Yi, Shuhong Deng, Yinan Yang, Yang |
author_sort | Yang, Jianming |
collection | PubMed |
description | BACKGROUND: Recent studies have proved that tenofovir disoproxil fumarate (TDF) is associated with a lower risk of hepatocellular carcinoma (HCC) occurrence in chronic hepatitis B (CHB) patients and HCC recurrence in patients who underwent hepatectomy when compared to ETV. However, it is unclear whether TDF and ETV treatment, which are both recommended as first-line antiviral agents to prevent the hepatitis B (HBV) recurrence after liver transplantation (LT), are associated with equivalent prognosis. We aim to compare risk of HCC recurrence and survival of patients recieving TDF or ETV after LT for HBV-related HCC. METHOD: We performed a retrospective study including 316 patients who received treatment with ETV or TDF after LT for HBV-related HCC from 2015 January to 2021 Augest. The Recurrence-free survival (RFS) and overall survival (OS) of TDF and ETV groups were analyzed and compared by propensity score-matched (PSM), multivariable Cox regression analysis, competing risk analysis, sensitivity analyses and subgroup analyses. RESULT: Compared with ETV, TDF therapy was associated with significantly higher RFS rates in the entire cohort (P < 0.01), PSM cohort (P < 0.01) and beyond-Milan cohort (P < 0.01). By multivariable analysis, TDF group was associated with significantly lower rates of HCC recurrence (HR, 0.33; 95%CI, 0.14–0.75; P < 0.01). In subgroup analyses, the similar results were observed in patients with following tumor characteristics: Maximum diameter plus number of viable tumor ≥ 5, with MIV or MAT, AFP at LT ≥ 20 ng/ml, and well or moderate tumor grade. CONCLUSION: Tenofovir decrease risk of HBV-Related Hepatocellular Carcinoma recurrence after liver transplantation compared to Entecavir. |
format | Online Article Text |
id | pubmed-9847063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98470632023-01-19 Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation Yang, Jianming Chen, Yewu Sun, Haobin Zhang, Xijian Wang, Jianfeng Liang, Zhixing Fu, Binsheng Zhang, Tong Yi, Shuhong Deng, Yinan Yang, Yang Infect Agent Cancer Research BACKGROUND: Recent studies have proved that tenofovir disoproxil fumarate (TDF) is associated with a lower risk of hepatocellular carcinoma (HCC) occurrence in chronic hepatitis B (CHB) patients and HCC recurrence in patients who underwent hepatectomy when compared to ETV. However, it is unclear whether TDF and ETV treatment, which are both recommended as first-line antiviral agents to prevent the hepatitis B (HBV) recurrence after liver transplantation (LT), are associated with equivalent prognosis. We aim to compare risk of HCC recurrence and survival of patients recieving TDF or ETV after LT for HBV-related HCC. METHOD: We performed a retrospective study including 316 patients who received treatment with ETV or TDF after LT for HBV-related HCC from 2015 January to 2021 Augest. The Recurrence-free survival (RFS) and overall survival (OS) of TDF and ETV groups were analyzed and compared by propensity score-matched (PSM), multivariable Cox regression analysis, competing risk analysis, sensitivity analyses and subgroup analyses. RESULT: Compared with ETV, TDF therapy was associated with significantly higher RFS rates in the entire cohort (P < 0.01), PSM cohort (P < 0.01) and beyond-Milan cohort (P < 0.01). By multivariable analysis, TDF group was associated with significantly lower rates of HCC recurrence (HR, 0.33; 95%CI, 0.14–0.75; P < 0.01). In subgroup analyses, the similar results were observed in patients with following tumor characteristics: Maximum diameter plus number of viable tumor ≥ 5, with MIV or MAT, AFP at LT ≥ 20 ng/ml, and well or moderate tumor grade. CONCLUSION: Tenofovir decrease risk of HBV-Related Hepatocellular Carcinoma recurrence after liver transplantation compared to Entecavir. BioMed Central 2023-01-17 /pmc/articles/PMC9847063/ /pubmed/36650583 http://dx.doi.org/10.1186/s13027-022-00478-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yang, Jianming Chen, Yewu Sun, Haobin Zhang, Xijian Wang, Jianfeng Liang, Zhixing Fu, Binsheng Zhang, Tong Yi, Shuhong Deng, Yinan Yang, Yang Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation |
title | Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation |
title_full | Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation |
title_fullStr | Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation |
title_full_unstemmed | Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation |
title_short | Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation |
title_sort | tenofovir versus entecavir on decreasing risk of hbv-related hepatocellular carcinoma recurrence after liver transplantation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847063/ https://www.ncbi.nlm.nih.gov/pubmed/36650583 http://dx.doi.org/10.1186/s13027-022-00478-4 |
work_keys_str_mv | AT yangjianming tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation AT chenyewu tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation AT sunhaobin tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation AT zhangxijian tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation AT wangjianfeng tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation AT liangzhixing tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation AT fubinsheng tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation AT zhangtong tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation AT yishuhong tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation AT dengyinan tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation AT yangyang tenofovirversusentecavirondecreasingriskofhbvrelatedhepatocellularcarcinomarecurrenceafterlivertransplantation |